8-K: Veracyte Reports Strong Preliminary Q4, Full-Year 2025 Results

Veracyte announced preliminary unaudited financial results for Q4 and full-year 2025, showing significant revenue and testing volume growth, and initiating positive 2026 guidance.

Summary

• Preliminary total revenue for Q4 2025 is expected to be between $138 million and $140 million, an increase of 16% to 18% compared to Q4 2024.
• Preliminary testing revenue for Q4 2025 is expected to be between $134 million and $136 million, an increase of 19% to 21% compared to Q4 2024.
• Preliminary testing volume for Q4 2025 is expected to be approximately 45,500 tests, an increase of 16% compared to Q4 2024.
• Preliminary total revenue for full-year 2025 is expected to be between $515 million and $517 million, an increase of approximately 16% compared to full-year 2024.
• Preliminary testing revenue for full-year 2025 is expected to be between $491 million and $493 million, an increase of approximately 17% to 18% compared to full-year 2024.
• Preliminary testing volume for full-year 2025 is expected to be approximately 169,700 tests, an increase of 19% compared to full-year 2024.
• Decipher volume for full-year 2025 is approximately 102,000, an increase of 27%.
• Afirma volume for full-year 2025 is approximately 67,700, an increase of 11%.
• Adjusted EBITDA margin for full-year 2025 is expected to be greater than 25%.
• Veracyte is initiating 2026 total revenue guidance of $570 million to $582 million, representing 10% to 13% growth.
• 2026 testing revenue guidance is $559 million to $569 million, representing 14% to 16% growth, excluding new tests.
• 2026 adjusted EBITDA margin is expected to be 25%.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results for Q4 and full-year 2025, with significant revenue and testing volume growth. The company also provides positive 2026 guidance, including continued growth and a healthy adjusted EBITDA margin, along with plans for new product launches. While the results are preliminary and subject to audit, the overall tone and reported metrics are highly positive, indicating strong operational performance and future prospects.

Positives

• Strong preliminary Q4 2025 total revenue growth of 16% to 18% ($138M-$140M).
• Robust preliminary Q4 2025 testing revenue growth of 19% to 21% ($134M-$136M).
• Significant preliminary Q4 2025 testing volume growth of 16% (approx. 45,500 tests).
• Solid preliminary full-year 2025 total revenue growth of approximately 16% ($515M-$517M).
• Strong preliminary full-year 2025 testing revenue growth of approximately 17% to 18% ($491M-$493M).
• High preliminary full-year 2025 testing volume growth of 19% (approx. 169,700 tests).
• Decipher volume increased by 27% to approximately 102,000 tests for full-year 2025.
• Afirma volume increased by 11% to approximately 67,700 tests for full-year 2025.
• Adjusted EBITDA margin for full-year 2025 is expected to be greater than 25%.
• Positive 2026 financial outlook with total revenue growth of 10% to 13% ($570M-$582M) and testing revenue growth of 14% to 16% ($559M-$569M).
• Expected adjusted EBITDA margin of 25% for 2026.
• Plans for new product launches in the US market in 2026 (Prosigna and TrueMRD platform).

Negatives

• Preliminary financial results are unaudited and subject to change upon completion of financial closing procedures and audit.
• Inability to provide an estimate of net income margin (GAAP measure) or related reconciliation tables for full-year 2025 without unreasonable effort due to unavailability of reliable estimates for certain components.

Risks

• Ability to launch, commercialize, and receive reimbursement for products.
• Ability to execute on business strategies relating to the C2i Genomics acquisition, integration of the business, and realization of expected benefits and synergies.
• Ability to demonstrate the validity and utility of genomic tests and biopharma/other offerings.
• Ability to continue executing on the business plan.
• Ability to continue to scale global operations and enhance the internal control environment.
• Impact of the war in Ukraine and other regional conflicts on European economies.
• Impact of foreign currency fluctuations, volatile interest rates, and inflation.
• Impact of legislation and policies enacted by the current U.S. administration.
• Turmoil in the global banking and finance system.
• Ongoing conflict in the Middle East.
• Performance and utility of tests in the clinical environment.

Future Outlook

Veracyte is initiating 2026 total revenue guidance of $570 million to $582 million (10% to 13% growth) and testing revenue guidance of $559 million to $569 million (14% to 16% growth, excluding new tests). The company also expects a 2026 adjusted EBITDA margin of 25%. Management is excited for continued Decipher and Afirma growth, as well as the launch of Prosigna and the TrueMRD platform in the US market in 2026, which are expected to further expand patient reach and financial performance.

Management Comments

• I am immensely proud of the impact our tests have had on the more than 800,000 patients we have served since the company's inception.
• We ended 2025 with another strong quarter of testing revenue growth and further expanded our patient impact.
• Looking ahead to 2026, I'm excited for continued Decipher and Afirma growth, as well as the launch of Prosigna and our TrueMRD platform in the US market, which we believe will further catalyze our patient reach and financial performance.

Industry Context

Veracyte operates in the global cancer diagnostics industry, leveraging genomic and clinical data, bioinformatics, and AI capabilities to develop high-performing cancer tests. The company's focus on durable reimbursement and guideline inclusion for its tests, along with continuous innovation and pipeline development, positions it within a competitive and rapidly evolving sector driven by advancements in precision medicine and personalized diagnostics.

Stakeholder Impact

• Shareholders: Positive preliminary financial results and optimistic 2026 guidance could lead to increased investor confidence and potential share price appreciation.
• Patients: The company emphasizes serving over 800,000 patients since inception and plans to expand patient reach with new product launches, indicating continued positive impact on patient care.
• Clinicians: Empowered with high-value insights from Veracyte's cancer tests to guide and assure patients.
• Employees: Continued growth and new product launches may indicate job stability and potential for expansion.

Next Steps

• Completion of financial closing procedures and audit for Q4 and full-year 2025 results.
• Reporting of full audited Q4 and 2025 financial results during an earnings call in February 2026.
• Launch of Prosigna in the US market in 2026.
• Launch of the TrueMRD platform in the US market in 2026.
• Continued growth of Decipher and Afirma tests.

Key Dates

Recommendation

The preliminary results demonstrate robust growth across key financial metrics, including total revenue, testing revenue, and testing volume for both Q4 and the full year 2025. The adjusted EBITDA margin exceeding 25% for 2025, coupled with positive 2026 guidance for continued revenue growth (10-16%) and a maintained 25% EBITDA margin, signals strong operational performance and profitability. The planned launch of new products like Prosigna and TrueMRD in the US market in 2026 provides additional catalysts for future growth and market expansion. While the results are preliminary, the consistent positive trends and clear growth strategy make Veracyte an attractive investment in the cancer diagnostics sector.

Keywords

cancer diagnostics, genomic tests, Veracyte, VCYT, financial results, revenue growth, EBITDA margin, Decipher, Afirma, Prosigna, TrueMRD, biopharma, SEC filing, 8-K